If you are a premium member make sure you sign in to see All the exclusive content In This Issue.
This week’s Microcap Information Arbitrage Weekly Wrap-Up is ready — spotlighting key moves, missed signals, and overlooked opportunities in our 1,500+ coverage universe built since 2009.
Summary Of What’s In This Weekly Wrap-Up
This week’s coverage primarily included earnings highlights from Luminar Media Group, Inc. (OOTC:LRGR) & Flexible Solutions International (NYSE:FSI), news of Zoned Properties, Inc. (OTCQB:ZDPY) going private, and a new addition to our Run To $1.00 Model Portfolio which has also quietly signaled that it might be a takeover candidate. I also recorded two Skull Sessions that focused heavily on trend investing.
Key highlights this week include:
- A Skull Session with Cyclop SpaceTech on capital flows and emerging business models in the space economy.
- A second Skull Session with Aurelion Research on small- and mid-cap idea generation in overlooked sectors.
- A new company (Sign in or join today to reveal name) was added to the Run to $1 Model Portfolio following regulatory and partnership updates.
- Zoned Properties, Inc. (OTCQB:ZDPY) announced agreements to sell and liquidate all assets ahead of a potential reverse merger.
- Luminar Media Group, Inc. (OOTC:LRGR) released preliminary Q4 2025 operating metrics showing continued funding growth.
- Flexible Solutions International (NYSE:FSI) reported preliminary Q4 sales below estimates while outlining contract-driven 2026 expectations.
Looking ahead, another Skull Session will feature Buda Juice, Inc. (NYSE:BUDA), which recently went public on the NYSE with a $20M IPO. On January 29, we’ll meet with Horatio Lonsdale-Hands, CEO and co-founder of BUDA. It has already achieved profitability, with $9.71M in revenue and $2.86M in net income for the first nine months of 2025, and we’ll explore plans to scale nationally while maintaining margins.
In addition, while not on the morning emails, we issued a premium tweet alert on Interpace Biosciences, Inc. (OOTC:IDXG)’s 2026 guidance, completion of preferred stock conversion, and uplisting plans. The company projects $40M in 2026 revenue, a 16% growth rate and entirely from its Thyroid testing business (company had shuttered its other business line because of insurance reimbursement issues).
——
Sorry, the full post is only available for paying subscribers. If you are already a paying subscriber, please make sure you are logged in. To become a paying subscriber please click on the link below
(We also offer a new very popular monthly subscription option).
gain Exposure to our expanded coverage on Our 1500+ Microcap Universe, Subscribe below.
200+ multibaggers and counting
GeoInvesting is a premier research platform for microcap investors, dedicated to uncovering high-potential stock ideas in undervalued companies across various sectors. With over 30 years of investing experience, GeoInvesting has covered more than 1,500 equities, providing often actionable proprietary research. The platform has been instrumental in identifying 200+ multibagger stocks, and offers investors exclusive access to over 600 management interview clips, allowing for deeper due diligence and understanding of the microcap stocks, many of which make it to market-beating premium Model Portfolios. Join the GeoInvesting community for the best stock research and microcap insights to help you stay ahead in the market. To learn more about our Premium Services, go here.. (https://geoinvesting.com/premium-research/)